A Belantamab Mafodotin Revival in Multiple Myeloma Therapy

N Engl J Med. 2024 Aug 1;391(5):461-462. doi: 10.1056/NEJMe2406799.

Authors

Suzanne Trudel¹, A Keith Stewart¹

Affiliation

¹ From the Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto.

PMID: 39083777
DOI: 10.1056/NEJMe2406799

No abstract available

Publication types

Editorial

MeSH terms

Antibodies, Monoclonal, Humanized* / administration & dosage
Antibodies, Monoclonal, Humanized* / adverse effects
Antineoplastic Agents / administration & dosage
Antineoplastic Agents / adverse effects
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Clinical Trials, Phase III as Topic
Humans
Multicenter Studies as Topic
Multiple Myeloma* / drug therapy
Multiple Myeloma* / mortality
Progression-Free Survival
Randomized Controlled Trials as Topic

Substances

Antibodies, Monoclonal, Humanized
Antineoplastic Agents
belantamab mafodotin